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Introduction
Bone marrow-derived mesenchymal stem cells (MSC) 
belong to a wider group of mammalian adult stem cells 
broadly defined as fibroblastic-like, plastic-adherent, non-
haematopoietic cells possessing self-renewal properties and 
the capacity to differentiate in vitro into adipocytes, chon-
drocytes and osteoblasts.1–3 MSC have been widely reported 
to have immunomodulatory capacity and an immunoprivi-
leged status.4–7 The lack of major histocompatibility class II 
(MHC II) and co-stimulatory molecules CD40, CD80 and 
CD86 and low MHC I expression by MSC is thought to be 
in part responsible for their immunoprivileged status.8 
Immunosuppressive properties offer potential utility of 
MSC in cell-based therapies such as in the prevention of 
graft versus host disease (GvHD) following allogeneic bone 
marrow transplantation9–11 and in the treatment of autoim-
mune diseases.12 Immunoprivileged status would mean that 
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allogeneic MSC could be used without the risk of immune 
rejection, a scenario that is attractive for commercial com-
panies to develop ‘off-the-shelf’ cell therapies and tissue-
engineered products. To date, although the published data 
regarding their immunosuppressive properties are compel-
ling, the evidence for the immunoprivileged status of alloge-
neic MSC is controversial.13–16
Most of the evidence for MSC immunoprivilege and 
immunosuppression has been obtained using adaptations 
of the lymphocyte transformation assays (LTA) and mixed 
lymphocyte reaction (MLR), respectively. These assays 
have been widely used for nearly five decades as in vitro 
correlates for alloreactivity, for the determination of histo-
incompatibility in tissue matching and as tests for immu-
nological tolerance.17–19 The reliability and sensitivity of 
these assays is dependent upon the optimisation of the 
assay conditions, and different conditions have yielded 
conflicting outcomes in some instances.
An important consideration for clinical application of 
allogeneic MSC is their potential for differentiation. 
Applications, which may involve tissue or organ regenera-
tion, require MSC differentiated into tissue-specific cells. 
However, differentiation has been reported to lead to the 
loss of both immunosuppressive properties and immuno-
privileged status,20–22 and this would be a major concern 
for clinical applications.
In light of the reported immunoprivilege of MSC, we 
hypothesised that depending on assay conditions, alloge-
neic MSC would be capable of stimulating a proliferative 
response in allogeneic lymphocytes. Hence, the aims of this 
study were to investigate the (1) immunogenicity and (2) 
immunomodulatory properties of both undifferentiated and 
differentiated allogeneic bone marrow-derived MSC using 
adaptations of the LTA and MLR, respectively. We 
employed an allogeneic mouse model in which Balb/c (H2-
d) and C3H (H2-k) mice were used as responder (recipient) 
and stimulator (donor), respectively. Dermal fibroblasts 
(DF) were used as controls for cells of mesenchymal origin 
and similarly tested. Unlike in standard MLR and LTA, 
which are commonly carried out over a 2–5-day period, 
assays were carried out over a 15-day period accompanied 
with medium replacement at 3-day intervals. We report that 
undifferentiated allogeneic MSC are immunogenic in LTA. 
Following chondrogenic differentiation, both allogeneic 
MSC and DF significantly stimulated lymphocyte prolif-
eration. With regard to immunomodulatory properties, both 
undifferentiated and chondrogenic-differentiated alloge-
neic and syngeneic MSC and DF suppressed lymphocyte 
proliferation in one- and two-way MLR.
Materials and methods
Animals
Female Balb/c (H2-d) and C3H (H2-k) mice were obtained 
from (Harlan Laboratories, UK) and maintained in the 
University of Leeds Central Biomedical Services with 
food and water administered ad libitum. MSC and DF 
were isolated from 4–8-week-old mice, while mononu-
clear cells (MNC) were isolated from 6- to 12-week-old 
mice. Animals were humanely sacrificed using a Schedule 
1 procedure in accordance with institutional and national 
guidelines.
Isolation and expansion of MSC and DF
MSC. MSC were isolated from the femurs of Balb/c and 
C3H mice using an adaptation of the plastic adherence 
method described by Phinney et al.23 Briefly, following 
femoral aspiration, the resulting cell suspensions were 
plated at a density of 105 cells cm−2 in T25 flasks (Nunc, 
Denmark) in culture medium (Dulbecco’s modified 
Eagle’s medium-low glucose (DMEM-LG; Invitrogen), 
10% (v/v) foetal calf serum (FCS; Lonza, UK), 2 mM 
l-glutamine and 100 U mL−1 penicillin/streptomycin (Inv-
itrogen, UK)).  The cells were incubated in a humidified 
incubator at 37°C in an atmosphere of 5% (v/v) CO2 in air 
for 24 h before the first medium change. Culture medium 
was changed every 3–4 days and cells were passaged using 
Hy-Q-Tase™ (Thermo-Fisher Scientific, UK). Cultures 
were maintained up to passage 15 (P15).
DF. DF were isolated using an adaptation of the method 
described by Kitano and Okada.24 Briefly, abdominal skin 
pieces (~2 cm2) were incubated in 0.5 mg mL−1 dispase II 
(Sigma) overnight at 4°C. The dermis was separated from 
the epidermis and digested in 0.5 mg mL−1 collagenase 1A 
(Sigma) at 37°C for 4 h. The cell suspensions were washed 
and cultured in Dulbecco’s modified Eagle’s medium-high 
glucose (DMEM-HG; Lonza) plus 10 (v/v) FCS, 2 mM 
l-glutamine and 100 U mL−1 penicillin/streptomycin. Cul-
ture medium was changed every 3–4 days and subsequent 
passages carried out 0.05% (v/v) trypsin–ethylenediami-
netetraacetic acid (EDTA; Lonza).
Characterisation of Balb/c and C3H MSC and 
DF
Flow cytometry. The following mouse-specific antibodies 
were used and, unless indicated, were obtained from eBio-
science, UK; fluorescein isothyocyanate (FITC)-conju-
gated anti-Sca-1 (clone D7), CD90.2 (clone 5a-8; 
Invitrogen), CD80 (clone 16-10A1), CD11b (clone 
M1/70), MHC I (clone 34-1-25), MHC II (clone 
M5/114.15.2), CD44 (clone IM7), phycoerythrin (PE)-
conjugated anti-CD29 (clone HMb1-1), CD86 (clone 
PO3.1) and CD45 (clone 30-F11; Invitrogen). The follow-
ing isotype controls were used: FITC-conjugated 1gG2a 
(clone 6H3) (MBL), IgG2b (clone 3D12) (MBL), IgG 
(clone 2E12), PE-conjugated IgG2b (clone 3D12) (Invit-
rogen) and IgG (clone 2E12). Briefly, cells were detached 
using Hy-Q-Tase™ (MSC) or 0.05% (v/v) trypsin-EDTA 
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(DF), washed and resuspended at 106 cells mL−1 in phos-
phate-buffered saline (PBS; Lonza). Equal volumes (200 
µL) of cell suspension and blocking buffer (PBS and 20% 
(v/v) FCS) were mixed and incubated for 20 min. Specific 
conjugated antibody solutions were added to the cell sus-
pensions followed by further incubation for 1 h at 4°C in 
the dark. The labelled cells were then washed thrice, resus-
pended in cold PBS and analysed on a FACSCalibur 
cytometer. Data were collected at 105 events and analysed 
using CellQuest software (BD Biosciences, UK) and 
FlowJo (Tree Star, USA).
Tri-lineage differentiation. MSC and DF multipotency was 
tested by differentiation into adipocytes, chondrocytes and 
osteocytes using adaptations of methods described in Tro-
pel et al.2 Culture medium supplements and chemicals 
were obtained from Sigma, UK, unless stated otherwise.
For adipogenic differentiation, MSC (P10) and DF (P6) 
were seeded into 6-well plates at 105 cells per well and 
cultured until 90% confluent at which point they were 
incubated in adipogenic differentiation medium (ADM) 
comprising culture medium with 1 µM dexamethasone, 
0.1 µM indomethacin, 0.5 mM 3-isobutyl-1-methylxan-
thine and 10 µg mL−1 insulin. ADM was interchanged with 
maintenance medium (culture medium with 10 µg mL−1 
insulin) every 2 days and the cycle repeated for 14 days. 
The presence of intracellular lipids was detected by oil 
red-O staining as described in Vidal et al.25 For osteogenic 
differentiation, cells were similarly seeded as previously 
described. On confluence, the cells were incubated in oste-
ogenic differentiation medium (culture medium with 0.1 
µM dexamethasone, 0.1 mM ascorbic-2-phosphate and 10 
mM β-glycerophosphate). Calcium deposition was ana-
lysed using alizarin red-S staining as described in Vidal et 
al.25 Chondrogenic differentiation was assessed using 
modifications of the micromass culture described in 
Denker et al.26 Briefly, 10 µL of MSC or DF (107 cells 
mL−1) was plated as micromass cultures in 24-well plates 
in chondrogenic differentiation medium (culture medium 
with 0.15 mM ascorbic 2 phosphate, 0.1 µM dexametha-
sone, 1 mM pyruvic acid, 6.25 µg mL−1 selenous acid, 
transferrin and insulin and 0.01 µg mL−1 transforming 
growth factor-β3 (TGFβ3). The cells were incubated for 
21 days with medium changed every 3 days. 
Chondrogenesis was assessed using alcian blue (Biostain 
Ready Reagents, UK) as described in Denker et al.26 All 
controls (non-differentiation conditions) for the tri-lineage 
assay were cultured in the DMEM-LG (MSC) or 
DMEM-HG (DF) culture medium.
Immunological assays
Isolation of Balb/c and C3H MNC. MNC were isolated from 
mouse spleens and lymph nodes (inguinal and axillary) as 
described in Bøyum.27 Briefly, tissues were gently teased 
and passed through a cell sieve using transport medium 
(Roswell Park Memorial Institute (RPMI)-1640 medium, 
20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) buffer (Sigma, UK) and 100 µg mL−1 peni-
cillin/streptomycin) followed by density gradient separa-
tion using Lymphoprep™ (Axis-Shield, UK). The resultant 
cell suspension was washed, counted using the Trypan blue 
dye-exclusion method and resuspended in lymphocyte cul-
ture medium [LCM] (RPMI-1640, 10% v/v FCS, 20 mM 
HEPES buffer, 2 mM l-glutamine, 50 mM 
β-mercaptoethanol and 100 U mL−1 penicillin/
streptomycin).
Mitotic inactivation. C3H MNC, MSC and DF and Balb/c 
MSC and DF used in LTA and MLR were mitotically inac-
tivated by treatment with 10 µg mL−1 mitomycin-C for 30 
min followed by five washes with transport medium and 
final re-suspension in lymphocyte culture medium.
Medium changes for MLR and LTA cultures. Medium changes 
were performed every 3-day period for all LTA and MLR 
cultures. Briefly, half the culture medium volume (100 µL) 
was aseptically removed from each well and an equal vol-
ume of fresh LCM was replaced.
Measurement of lymphocyte proliferation. After incubation, 
LTA and MLR cultures were pulsed with 10 µL per well of 
0.025 µCi (2 Ci mmol−1) 3H-thymidine (Perkin-Elmer, 
UK) for the last 16 h of each time point. Upon completion 
of incubation, the cells were harvested and 3H-thymidine 
incorporated into cellular DNA was measured with raw 
data obtained as counts per minute (CPM). Lymphocyte 
stimulation for LTA and MLR as represented by stimula-
tion index (SI) was calculated using the formula
SI
MeanCPM in stimualted cultures
LTAor MLR
MeanCPM inunstimula
=
( )
ted cultures
Responder only control( )
LTA. Responder Balb/c MNC (5 × 104 cells per well) were 
co-cultured with mitomycin-C-treated and untreated C3H 
MSC or DF (allogeneic LTA) and Balb/c MSC or DF (syn-
geneic LTA) at a 1:1 cell ratio (n = 6) in uncoated 96-well 
plates (Sterilin, UK). Positive controls (n = 6) comprised 
Balb/c MNC stimulated with 10 µg mL−1 concanavalin-A 
(Con-A). Negative controls (n = 6) comprised Balb/c 
MNC alone. The cultures were incubated for 3, 6, 9, 12 
and 15 days accompanied by medium changes every 3 
days. Lymphocyte proliferation was measured by 3H-thy-
midine uptake.
MLR. Mixed lymphocyte cultures comprising responder 
Balb/c MNC (5 × 104 cells) and mitomycin-C-treated 
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(one-way MLR) or untreated (two-way MLR) stimulator 
C3H MNC were co-cultured in the presence of Balb/c and 
C3H MSC or DF at a 1:1:1 ratio in 200 µL of lymphocyte 
culture medium (n = 6). Positive controls for allogeneic 
stimulation comprised co-cultures of Balb/c MNC and 
C3H MNC only. Balb/c MNC were used as controls for 
non-proliferating cells. To test for mitotic inactivation, 
monocultures of untreated and mitomycin-C-treated C3H 
MNC were either left unstimulated or stimulated with 10 
µg mL−1 Con-A. Similarly, individual cultures of unstimu-
lated and Con-A-stimulated Balb/c and C3H MSC and DF 
were used as controls. The cultures were incubated for 3, 
6, 9, 12 and 15 days accompanied by medium changes 
every 3 days. Lymphocyte proliferation was measured by 
3H-thymidine uptake.
LTA and one-way MLR for chondrogenic-differentiated MSC 
and DF. Balb/c and C3H MSC (P5) and DF (P5) were dif-
ferentiated in pellet culture as described by Bosnakovski et 
al.28 Briefly, 1 × 106 cells were pelleted at 500g for 10 min 
and incubated for 21 days in chondrogenic differentiation 
medium with medium changes after 3 days. On comple-
tion, the cell pellets were disaggregated using 100 µg mL−1 
collagenase 1A for 30 min at 37°C, washed and resus-
pended in fresh lymphocyte culture medium. The cells 
were seeded at 5 × 104 cells in 20 µL medium in uncoated 
V-bottom 96-well plates (Sterilin, UK) and incubated 
overnight. The next day, Balb/c MNC (LTA) or Balb/c 
MNC + mitomycin-C-treated C3H MNC (one-way MLR) 
were added to each well and the cultures were treated as 
described above.
Statistical analysis
All statistical analyses were carried out using Microsoft® 
Excel 2010 and GraphPad Prism® (GraphPad, USA). All 
replicate CPM data from LTA and MLR at each time point 
were first transformed to Log10 prior to analysis by one-
way analysis of variance (ANOVA). Differences between 
means at each time point were calculated using the mini-
mum significant difference (MSD) at 95% confidence 
limit (CL) by the T-method for equal samples sizes and the 
T′-method for unequal sample sizes. The means, upper and 
lower 95% CL obtained from Log10 transformed data were 
then back-transformed and the data were plotted as mean 
values ± 95% CL.
Results
MSC and DF share morphological and 
phenotypical similarities
Balb/c and C3H MSC were harvested by femoral aspira-
tion and isolated using their propensity to adhere to tissue 
culture plastic. Non-adherent cells were lost during 
ensuing medium changes. Initial cultures were composed 
of sparse cells with several distinct morphologies. After 
the first passage, it took an average of 3–4 weeks for the 
cells to reach confluence. At P3, the proliferative capacity 
of the cells increased dramatically and homogeneous cul-
tures of bipolar, spindle-shaped fibroblastic-like cells 
ensued with an average cell doubling time (CDT) of 8–12 
h (Figure 1(a)). These cultures retained their morphologi-
cal homogeneity up to the P15. DF cultures were homoge-
neously fibroblastic throughout culture (Figure 1(b)) and 
morphologically similar to P3-P15 MSC.
The phenotype of both Balb/c and C3H MSC was 
determined by flow cytometry using a panel of markers 
commonly used in stem cell analysis. P3 (early) and P12 
(late) cultures were analysed to determine whether pro-
longed culture led to any phenotypic changes. Both Balb/c 
and C3H P3 (Figure 1(c)) and P12 MSC exhibited a simi-
lar phenotype consistent with that attributed to MSC. 
Sca-1 and CD44 were highly expressed (>95%) by MSC at 
both passages (Table 1). CD29 and CD90.2 expression 
was greater than 95% in all but P3 C3H MSC (89% and 
87%, respectively). MHC I expression was partial in both 
P3 and P12 C3H (77 and 57%) and Balb/c MSC (62% and 
57%). CD105 expression was higher in P12 (>95%) than 
P3 MSC (<60%). MHC II, CD11b, CD34, CD45, CD80 
and CD86 were negative (<5%) in all MSC samples.
DF were also analysed using the same markers for MSC 
(except CD34). Due to their fast growth, only intermediate 
passage (P6) cells were analysed. Both Balb/c and C3H 
DF were positive for Sca-1, MHC I and CD29 but were 
negative for MHC II, CD11b, CD45, CD80, CD86, CD105 
and expressed intermediate levels of CD44 and CD90.2 
(Figure 1(d)). Of the positive markers, only Sca-1 had 
greater than 95% expression. CD90.2, MHC I and CD29 
expression was 54%, 91% and 90%, respectively, for 
Balb/c and 78%, 82% and 80%, respectively, for C3H 
(Table 1). All the negative markers had expression less 
than 5% in both types of DF. In the case of CD44, expres-
sion was 42% and 53%, respectively, in Balb/c and C3H 
DF. Collectively, the phenotype displayed by DF and MSC 
showed differences in the expression of CD105 (negative 
in DF and positive in MSC) and CD44 (intermediate in DF 
and positive in MSC). There were also some variations in 
marker expression between the two mouse species and dif-
ferent cell passages.
MSC and DF exhibit similar differentiation 
capacity
P10 Balb/c and C3H MSC were cultured in ADM, chon-
drogenic and osteogenic differentiation media. After incu-
bation, both Balb/c and C3H MSC tested positive for 
adipogenesis with oil red-O, chondrogenesis with alcian 
blue and osteogenesis with alizarin red-S (Figure 1(e)). 
Interestingly, both Balb/c and C3H DF underwent 
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adipogenic, chondrogenic and osteogenic differentiation 
when cultured and tested under the same conditions used 
for MSC (Figure 1(f)).
Allogeneic MSC stimulate lymphocyte 
proliferation
To test the immunoprivilege of allogeneic MSC, LTA incor-
porating 1:1 co-cultures of Balb/c MNC with either mito-
mycin-C-treated C3H (allogeneic) or Balb/c (syngeneic) 
MSC were cultured with half the medium changed and 
replaced at 3-day intervals during incubation. The cultures 
were then analysed for lymphocyte proliferation after 3, 6, 
9, 12 and 15 days. 3H-thymidine uptake counts between the 
syngeneic and allogeneic LTA were compared based on the 
premise that counts significantly greater than those in syn-
geneic LTA were indicative of a stimulatory response. At 
days 6 and 9, allogeneic LTA produced significantly (p < 
0.05) higher counts compared to syngeneic LTA with high-
est counts at day 6 (Figure 2(a)). This trend was also 
observed in LTA comprising mitotically active (mitomycin-
C untreated) C3H and Balb/c MSC as stimulators and 
Balb/c MNC. The counts obtained for syngeneic LTA were 
comparable to those from control Balb/c MNC monocul-
tures (Figure 2(b)). Interestingly, LTA involving Balb/c 
MNC and either mitomycin-C-treated or untreated synge-
neic and allogeneic DF failed to stimulate lymphocyte pro-
liferation at all the time points (Figure 2(c)). To demonstrate 
that the Balb/c MNC were viable, co-culture of these cells 
with Con-A resulted in significant stimulation (Figure 
Figure 1. Isolation and characterisation of mouse MSC and DF. P3) Mouse MSC (a) and DF (b) showed typical bipolar spindle-
shaped morphology (×100). Analysis of selected markers showed that MSC (c) and DF (d) differed in their expression of CD44 
and CD105 (results (c) and (d) representative for P3 and P10 Balb/c and C3H MSC and DF, respectively). Tri-lineage differentiation 
of P10 MSC (e) and P6 DF (f) was tested with oil red-O for adipogenesis, alcian blue for chondrogenesis and alizarin red-S for 
osteogenesis.
MSC: mesenchymal stem cells; DF: dermal fibroblasts.
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2(d)). Overall, only the SI of LTA involving mitotically 
active and inactivated allogeneic MSC were greater than 3 
at all the time points except for day 15 (Supplementary 
Figure 1). The mitomycin-C concentration (10 µg mL−1) 
used to mitotically inactivate the cells without impacting on 
cell viability was determined using carboxyfluorescein suc-
cinimidyl ester (CFSE) dilution (Supplementary Figure 2).
Allogeneic and syngeneic MSC and DF possess 
immunosuppressive properties
The immunosuppressive properties of MSC were tested in 
one-way MLR. Responder Balb/c MNC and mitotically 
inactivated stimulator C3H MNC were co-cultured with 
either C3H (allogeneic) or Balb/c (syngeneic) mitotically 
inactivated MSC at a 1:1:1 ratio for 3, 6, 9, 12 and 15 days 
with half the medium changed and replaced at 3-day inter-
vals. The positive control (Balb/c MNC + mitotically inac-
tivated C3H MNC) showed that Balb/c lymphocytes were 
significantly stimulated (p < 0.05) with 3H-thymidine 
uptake peaking at day 6 followed by a gradual decline in 
stimulation with time. When both syngeneic and alloge-
neic mitotically inactivated MSC were co-cultured in the 
one-way MLR, 3H-thymidine uptake was significantly 
suppressed at days 6, 9 and 12 with up to 90% suppression 
of the Balb/c response observed at day 6 with both alloge-
neic and syngeneic MSC (Figure 3(a)). In order to deter-
mine the immunosuppressive potency of MSC from each 
mouse strain, mitotically inactivated Balb/c and C3H MSC 
were cultured in two-way MLR. Both Balb/c and C3H 
MSC significantly suppressed the two-way MLR at days 
3, 6, 9 and 12 (Figure 3(b)). Interestingly, the counts for 
the two-way MLR control (Balb/c MNC + C3H MNC) 
were not significantly different from those of the one-way 
MLR. Overall, mitotically inactivated Balb/c and C3H 
MSC exhibited comparable potency in suppressing both 
the one-way and two-way MLR. In similar experiments to 
test the immunosuppressive potential of DF, 3H-thymidine 
uptake in one-way MLR cultures containing syngeneic or 
allogeneic DF was suppressed significantly (p < 0.05) at 
days 3, 6 and 9 (Figure 3(c)). Up to 75% of the one-way 
MLR was suppressed at day 6 by both allogeneic and syn-
geneic DF. A similar trend was observed in the two-way 
MLR in which approximately 80% of the response was 
suppressed by both C3H and Balb/c DF (Figure 3(d)). 
Collectively, these data showed that like MSC, DF were 
similarly immunosuppressive in both one- and two-way 
MLR. Significant suppression was however observed ear-
lier in MLR with DF (days 3–9) than in MLR with MSC 
(days 6–12). Some of the SI for both syngeneic and alloge-
neic MSC and DF mediated immunosuppression at spe-
cific time points were greater than 3 (Supplementary 
Figure 3).
Allogeneic chondrogenic-differentiated MSC 
and DF are immunosuppressive but stimulate 
lymphocyte proliferation
Chondrogenic-differentiated Balb/c and C3H MSC and 
DF were tested for their immunogenicity and immunosup-
pressive capacity. The controls for these experiments 
showed appropriate responses for unstimulated cells 
(Figure 4(a)) and con-A-stimulated cells (Figure 4(b)). In 
LTA involving allogeneic MSC-Chon or DF-Chon, signifi-
cant counts (p < 0.05) relative to the Balb/c MNC control 
were produced at days 3, 6 (peak) and 9 (Figure 4(c)) 
Table 1. Phenotypic characterisation of Balb/c and C3H MSC and DF by flow cytometry.
Marker C3H MSC Balb/c MSC C3H DF Balb/c DF
 P3 P12 P3 P12 P6 P6
Sca-1 97% 98.40% 95.30% 98% 98.40% 100%
MHC I 76.80% 57.30% 62.30% 56.50% 82% 90.90%
MHC II 0.10% 1.17% 2.80% 1.50% 1.20% 1.38%
CD11b 0% 1.30% 1.20% 0.80% 1.66% 1.57%
CD29 88.50% 97.40% 100% 100% 80.14% 90.30%
CD34 0.20% 0.21% 0.85% 0.14% – –
CD44 99% 97% 99.60% 100% 53.20% 42.10%
CD45 0.01% 0.74% 1.21% 1.24% 1.34% 0.10%
CD80 0.03% 3.02% 1.40% 1.20% 2.01% 1.14%
CD86 0.02% 1.03% 1.20% 1.04% 1.40% 2.85%
CD90.2 87% 98.80% 99.80% 100% 78% 54.20%
CD105 59% 99% 57% 99.20% 1.30% 1.49%
MHC I: major histocompatibility class I; MHC II: major histocompatibility class II; MSC: mesenchymal stem cells; DF: dermal fibroblasts.
Cultured early passage (P3) and late passage (P6) MSC and intermediate passage (P6) DF were stained with conjugated antibodies as described in 
section ‘Materials and Methods’. Events (10,000) were collected using a FACSCalibur cytometer and results were analysed using CellQuest and 
FlowJo software. Results are expressed as % of positively stained cells relative to isotype controls.
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showing that both the allogeneic were immunogenic. In 
the one-way MLR, the counts for the positive control 
peaked at day 6 and followed a similar trend seen before. 
When syngeneic and allogeneic MSC-Chon were co-cul-
tured in the one-way MLR, significant suppression (p < 
0.05) of 3H-thymidine uptake was observed at days 3, 6 
and 9 in comparison to one-way MLR positive control 
with approximately 50% suppression achieved at day 6 
(Figure 4(d)). A similar trend was obtained with syngeneic 
or allogeneic DF-Chon. There were no significant differ-
ences (p < 0.05) in the suppression of the one-way MLR 
between allogeneic or syngeneic MSC-Chon and DF-Chon. 
On the whole, the SI of allogeneic but not syngeneic MSC-
Chon and DF-Chon was equal to or greater than 3 at all the 
time points but day 15 for the LTA (Figure 4(e)). However, 
in the one-way MLR, SI equal to or higher than 3 was 
obtained in all cultures with either syngeneic or allogeneic 
differentiated MSC and DF at all the time points but day 
15 (Figure 4(f)).
Discussion
The aims of this study were to investigate the notions that 
allogeneic MSC are immunoprivileged7,29,30 and immuno-
suppressive5,31 even after differentiation8,32 in light of the 
immunoprivileged status of allogeneic MSC being brought 
into question.15,30,33 Here, our emphasis was on investigat-
ing both in vitro immunoprivilege and immunomodulation 
before and after chondrogenic differentiation using modi-
fications of the LTA and MLR. DF were employed as con-
trols, but showed striking similarities to MSC in some but 
not all cases.
The most important finding of this study was the dem-
onstration that allogeneic C3H MSC significantly stimu-
lated Balb/c MNC in LTA. Stimulation was measured by 
statistical comparison of 3H-thymidine uptake in LTA to 
Balb/c MNC only cultures, as well as computation of the 
SI, which according to the International Union of 
Immunological Societies (IUIS) in 1976, values equal to 
Figure 2. Immunogenicity of allogeneic mouse MSC and DF. For the LTA test for immunogenicity, responder Balb/c MNC (5 × 104 
cells per well) were co-cultured with stimulator C3H (allogeneic) and Balb/c (syngeneic) MSC (a) or DF (c) at a 1:1 ratio. Balb/c and 
C3H MNC and MSC (b) or DF (d) cultured alone or stimulated with Con-A were controls for non-proliferating and proliferating 
cells. Mitotically inactivated cells are highlighted in red. Culture medium was changed every 3 days by replacing 100 µL with an 
equal volume of fresh medium and the cells were cultured for 3, 6, 9, 12 and 15 days and lymphocyte proliferation measured by 
the incorporation of 3H-thymidine. CPM data (n = 6) were Log10 transformed to compute upper and lower 95% CL. Data were 
then back-transformed for presentation. Data are presented as mean CPM ± 95% CL. The symbol ‘*’ indicates significant difference 
between Balb/c MNC + C3H MSC and Balb/c MNC + Balb/c MSC (a); (e) at a given time point.
MSC: mesenchymal stem cells; DF: dermal fibroblasts; LTA: lymphocyte transformation assay; MNC: mononuclear cells; CPM: counts per minute; 
CL: confidence limit.
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or above 3 are deemed “statistical biological positive” or 
significant stimulation of responder lymphocytes by stim-
ulating agent.34,35 These findings were in contrast with 
most previous in vitro findings.30,31,33,36–38 Interestingly, 
although some in vitro studies have shown that allogeneic 
MSC were immunoprivileged, in vivo tests have suggested 
otherwise.14–16,30,33
These discrepancies raise the important question: 
whether in vitro assays are a reliable correlate for in vivo 
immunogenicity given the variations in methodologies 
across studies. For instance, in this study, the culture 
medium was changed during the course of incubation, an 
approach that has not been adopted in any of the previous 
studies. Another factor was the ratio of allogeneic MSC to 
responder lymphocytes. We used a 1:1 ratio after prelimi-
nary experiments showed that increasing the responder-to-
stimulator cell ratio from 1:1 to 1:5 resulted in a decrease 
in 3H-thymidine uptake and SI in cultures. This implied 
that increasing the MSC ratio would lead to inhibition of 
lymphocyte proliferation, which could be construed as 
immunoprivilege. Le Blanc et al.4 had previously demon-
strated using human MSC that low MSC doses were stim-
ulatory in LTA, while higher doses were inhibitory but this 
was not explored further. There is now overwhelming evi-
dence that MSC inhibit lymphocyte proliferation in a dose-
dependent manner and studies in which high 
MSC-to-lymphocyte ratios have been used resulted in no 
detectable lymphocyte stimulation.33,39 This suggests that 
the results of in vitro assays of immunogenicity will 
depend on the MSC-to-lymphocyte ratio.
Klyushnenkova et al.29 reported that MSC failed to 
stimulate allogeneic separated lymphocytes but when 
MSC were cultured with allogeneic unseparated peripheral 
blood mononuclear cells (PBMNC), the 3H-thymidine 
Figure 3. Immunomodulatory capacity of MSC and DF. To test for the immunosuppressive potency of allogeneic (C3H) and 
syngeneic (Balb/c) MSC and DF, one-way MLR comprising responder Balb/c MNC (5 × 104 cells per well) and mitotically inactivated 
stimulator C3H MNC were co-cultured with mitotically inactivated allogeneic or syngeneic (with respect to the responder) MSC 
(a) or DF (c) at a 1:1:1 cell ratio. Two-way MLR also comprising 1:1:1 co-cultures of Balb/c MNC with C3H MNC and mitotically 
inactivated Balb/c and C3H MSC (b) or DF (d). Mitotically inactivated cells are highlighted in red. Culture medium was changed 
every 3 days by replacing 100 µL with an equal volume of fresh medium and lymphocyte proliferation measured by 3H-thymidine 
uptake. CPM data (n = 6) were Log10 transformed to compute upper and lower 95% CL. Data were then back-transformed for 
presentation. Data (n = 6) are presented as mean CPM ± 95% CL. The symbol ‘*’ indicates significant difference between one-way 
MLR and one-way MLR + C3H/Balb/c MSC (a) or DF (c); two-way MLR and two-way MLR + C3H/Balb/c MSC (b) or DF (d) at a 
given time point.
MSC: mesenchymal stem cells; DF: dermal fibroblasts; LTA: lymphocyte transformation assay; MNC: mononuclear cells; MLR: mixed lymphocyte 
reaction; CPM: counts per minute; CL: confidence limit.
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counts were significantly higher at day 8 of culture than 
for PBMNCs cultured alone.Although not explored further 
by the authors, these findings suggested the role of acces-
sory cells in PBMNCs, particularly antigen-presenting cell 
(APC) in the response of responder lymphocytes to stimu-
lator MSC, a possible role for the indirect or semi-direct 
response. Another study which used porcine MSC failed to 
detect a proliferative response in an allogeneic LTA, 
although the opposite was found in in vivo tests using the 
same MSC.30 The allogeneic LTA was only tested for 3 
days and given that MSC are known to be poorly immuno-
genic, the in vitro findings could have simply been due to 
Figure 4. Immunogenicity and immunosuppressive properties of chondrogenic-differentiated MSC and DF. Monocultures of 
unstimulated (a) and con-A-stimulated (b) Balb/c and C3H MNC and chondrogenic-differentiated MSC and DF were used as 
controls for non-proliferating and proliferating cells, respectively. LTA for stimulatory capacity comprised co-cultures of responder 
Balb/c MNC (5 × 104 cells per well) and stimulator C3H (allogeneic) and Balb/c (syngeneic) chondrogenic-differentiated MSC or DF 
at a 1:1 ratio (c). One-way MLR test for immunosuppression comprised 1:1:1 ratios of co-cultures of responder Balb/c MNC with 
stimulator C3H MNC and allogeneic or syngeneic (with respect to the responder MNC) MSC and DF (d). Red indicates cells that 
were mitotically inactivated by treatment with mitomycin-C. Culture medium was changed every 3 days by replacing 100 µL with 
an equal volume of fresh medium. Lymphocyte proliferation was measured by the incorporation of 3H-thymidine. CPM data (n = 6) 
were Log10 transformed to compute upper and lower 95% CL. Data were then back-transformed for presentation. Data (n = 6) are 
presented as mean CPM ± 95% CL (a, c, e, g). The symbol ‘*’ indicates significant differences between Balb/c MNC only and Balb/c 
MNC + C3H differentiated MSC or DF (c) and between one-way MLR only and one-way MLR + C3H or Balb/c differentiated MSC 
and DF (d) at a given time point. Data are also presented as SI (b, d, f, h). The red line at SI = 3 denotes statistical biological positive 
whereby SI > 3 indicates significant stimulation of responder MNC.
MSC: mesenchymal stem cells; DF: dermal fibroblasts; LTA: lymphocyte transformation assay; MNC: mononuclear cells; MLR: mixed lymphocyte 
reaction; CPM: counts per minute; CL: confidence limit; SI: stimulation index.
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the limited time for an adequate response via the indirect 
or semi-direct pathway to be detected. In fact, there is a 
growing hypothesis that MSC employ an ‘evasive’ tactic 
rather than immunoprivilege, as recently argued by 
Ankrum et al.40 We suggest that in an in vitro setting, such 
‘evasive’ approaches in addition to limited incubation time 
can be further exaggerated by the declining nutrient 
reserves and accumulation of metabolic by-products thus 
hampering the detection of and initiation of an allogeneic 
response. Thus, our approaches to increase the incubation 
period to 15 days and introduce medium changes were 
aimed at remedying some of the shortcomings of the tradi-
tional LTA and MLR approach.
Interestingly, allogeneic C3H DF failed to stimulate 
Balb/c lymphocyte proliferation in LTA in contrast to C3H 
MSC at the 1:1 ratio. However, it must be noted that DF 
were tested only at this ratio, and thus, this result cannot be 
interpreted as demonstrative of DF immunoprivilege. 
Following chondrogenic differentiation, both allogeneic, 
but not syngeneic, MSC and DF stimulated lymphocyte 
proliferation. Collectively, the LTA findings suggested that 
both allogeneic MSC and DF may be immunologically 
rejected following implantation. Although undifferentiated 
allogeneic DF were non-stimulatory in LTA, their chon-
drogenic-differentiated progeny were stimulatory. 
Chondrogenic differentiation of MSC has been reported to 
render them immunogenic.21,22 Chen et al.22 reported that 
expression of CD80 and CD86 coupled with elevated lev-
els of MHC I were major contributors to the immuno-
genicity of chondrogenic-differentiated MSC.
Although DF have been widely used as control cells in 
some MSC studies,39 the evidence with regard to their 
immunogenicity is equally controversial. Human DF have 
previously been reported to be non-immunogenic, whereas 
smooth muscle, endothelial and epidermal cells were 
immunogenic.41 Our findings were similar to those 
reported in studies conducted nearly four decades ago;42 
yet the immunological properties of DF have only gained 
prominence in the last decade.
The unique approach taken in this study is that LTA and 
MLR experiments were carried out over a 15-day period 
instead of the traditional 3–5 days. This modification was 
borne out of the hypothesis that the traditional 3–5-day 
approach favours the direct pathway of allorecognition but 
not necessarily the indirect and semi-direct pathways, 
which are thought to require more time to be initiated both 
in vitro and in vivo.43,44 To mitigate for this extended cul-
ture period, medium changes (half the culture medium was 
replaced with an equal amount of fresh medium) at 3-day 
intervals were carried out. This was done to ensure consist-
ent nutrient supply to proliferating cells and avoiding dras-
tic pH changes. Lymphocyte stimulation is a highly 
energy-dependent process requiring increased glucose 
uptake and reduced oxygen intake, which lowers the pH 
and affects cell division and viability.45 Even when oxygen 
supply is maintained, stimulated lymphocytes undergo 
aerobic glycolysis, which, without nutrient replenishment, 
could lead to increased acidity and metabolic arrest.46 We 
tested Balb/c lymphocyte proliferation after stimulation by 
Con-A with and without medium changes. Significant 
lymphocyte stimulation lasted for 15 days in the former 
and 5 days in the later. This enabled us to conduct our 
experiments for longer periods than usual (Figure 5).
The one-way and two-way MLR were used to determine 
the immunomodulatory capacity of both allogeneic and 
syngeneic MSC. Significant suppression of responder lym-
phocyte proliferation was obtained in all cases. These find-
ings supported a growing body of evidence, which used 
mouse,33 human8,29 and primate31 models to demonstrate 
the in vitro immunosuppressive potency of MSC. Also, 
both syngeneic and allogeneic DF suppressed one-way and 
two-way MLR in a similar manner to that displayed by 
MSC. The overall suppression of one-way MLR by both 
syngeneic and allogeneic MSC and DF was between 60% 
and 95%, which was consistent with previous studies. 
Chondrogenic-differentiated allogeneic MSC and DF sig-
nificantly suppressed one-way MLR, although the suppres-
sion at day 6 (50%) appeared lower to that obtained with 
undifferentiated MSC and DF. Previous studies have shown 
that MSC lost their immunosuppressive potency following 
chondrogenic21,22 and osteogenic32 differentiation as well 
as in in vivo studies.20 The fact that both allogeneic and 
syngeneic MSC and DF suppressed one-way MLR sug-
gested that the mechanisms involved were independent of 
the MHC as has previously been reported with human 
MSC.4 The mechanisms by which MSC suppress lympho-
cyte proliferation in vitro are not fully understood. It is 
thought that suppression is mediated, at least in part by fac-
tors such as prostaglandin E2 (PGE2), indoleamine 2,3-diox-
ygenase (IDO), transforming growth factor-β1 (TGFβ1) 
and nitrous oxide (NO) secreted by MSC upon activation 
by allogeneic lymphocytes.5,7 However, other studies have 
suggested that neither MSC production of these factors was 
responsible for T-lymphocyte suppression.37 Cell-to-cell 
contact has been reported to be critical for MSC-mediated 
immunosuppression through induction of T-cell anergy,36 
although earlier studies showed that the responsiveness of 
T-cells that have been previously suppressed by MSC could 
be restored.47,48 It has been argued that fibroblast-mediated 
immunosuppression is independent of PGE2, IL-10 and 
IDO48,49 despite being similar to that exhibited by MSC.50 
This suggests that the immunosuppressive mechanisms 
employed by MSC and DF may be different but this is yet 
to be explored.
The phenotype of MSC has also been thought to con-
tribute to their perceived immunoprivilege. Their lack of 
MHC II, low to intermediate expression of MHC I and 
lack of co-stimulatory markers CD80, CD86 and CD40 
was demonstrated in this study in both low (P3) and high 
passage (P12) MSC. This phenotype renders MSC 
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incapable of directly stimulating allogeneic CD4+ helper 
lymphocytes. However, even in the absence of the direct 
pathway, MSC could potentially stimulate allogeneic 
CD4+ lymphocytes via the indirect or semi-direct path-
ways in the presence of accessory cells. For this reason, we 
used unseparated MNC in all the experiments. However, it 
will be important for future studies of the mechanisms of 
MSC- and DF-mediated immunomodulation to investigate 
the roles of these allorecognition pathways.
To our knowledge, this study is the first to demonstrate 
the tri-lineage differentiation potential of both mouse MSC 
and DF into adipocytes, chondrocytes and osteocytes. This 
test remains the only functional assay for defining MSC. 
Although it has been widely reported that DF are capable of 
differentiation into cells of other types, their tri-lineage 
capacity remains controversial. Previous studies have dem-
onstrated their inability to differentiate or their capacity to 
differentiate into either one or two39,51,52 but not all the three 
cell lineages. A growing school of thought suggests that 
MSC and DF are phenotypically and functionally indistin-
guishable.53,54 However, we found differences in the expres-
sion of CD44 and CD105, which were strongly expressed in 
MSC but weakly (CD44) or not (CD105) expressed in DF. 
Wagner et al.55 reported that human fibroblasts expressed 
CD44 but not CD105 and were incapable of differentiation 
into fat and bone. These differences in marker expression, 
although providing a measure of distinction, are unreliable 
since MSC from different species and studies have been 
found to have different marker expression profiles.
Conclusion
Our findings and the available literature demonstrated the 
complexity of studying the immunological properties of 
MSC in vitro as well as the difficulty of distinguishing 
between MSC and DF. The results have shown that undif-
ferentiated and differentiated allogeneic MSC, although 
potent immunosuppressors, were immunogenic.
Figure 5. Effect of medium replacement on Balb/c MNC proliferation. Cells (1 × 105 cells per well) were stimulated with Con-A 
(5–25 µg mL−1) and cultured for 3, 5, 10, 15 and 20 days with and without medium changes. The medium changes were carried out 
every 3 days by replacing 100 µL of medium per well. Unstimulated cells (no Con-A) were used as controls for non-proliferating 
cells. CPM data (n = 6) were Log10 transformed to compute upper and lower 95% CL. Data were then back-transformed for 
presentation and is presented as mean CPM ± 95% CL for cultures (a) with medium changes and (b) without medium changes. 
Lymphocyte stimulation is also presented as SI for cultures (c) with and (d) without medium changes. The red line at SI = 3 denotes 
statistical biological positive; only SI above 3 were considered significant responses against Con-A.
MNC: mononuclear cells; CPM: counts per minute; CL: confidence limit; SI: stimulation index.
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Supplementary Information
Supplementary Figure 1. Stimulation of Balb/c responder MNC by allogeneic MSC and DF. LTA to determine the 
immunogenicity of C3H (allogeneic) and syngeneic (Balb/c) MSC (A) and DF (B) were set up as described in Figure 2. CPM data 
were used to compute the SI, which is a ratio of 3H-thymidine uptake between responder MNC alone and co-cultures of responder 
MNC + MSC or DF. The red line at SI = 3 denotes statistical biological positive whereby SI > 3 indicates significant stimulation of 
responder MNC.
Supplementary Figure 2. CFSE dilution assay for the determination of mitotic inactivation of stimulator C3H MHC. 
Representative histograms plotted to show CFSE fluorescence intensities of unstimulated cells (A) and Con-A stimulated cells (B) 
treated with 5 and 10 µg.ml−1 mitomycin C. Positive (Con-A stimulated) and negative (unstimulated) control cells were not treated 
with mitomycin C. A shift to the left of peak fluorescence intensities denotes CFSE dilution which in turn represents separate cell 
fractions of daughter cells. The peaks of the Con-A stimulated cells were further resolved using the cell proliferation platform on 
FlowJo™ to expose groups of cells with the different CFSE fluorescence intensities which corresponded to specific generations of 
cell division (C). The data are representative of three experiments.
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Supplementary Figure 3. Suppression of the one-way and two-way MLR by mouse MSC and DF. One-way MLR to determine 
the immunosuppressive properties of C3H (allogeneic) and syngeneic (Balb/c) MSC (A) and DF (C) as well as two-way MLR to 
determine the suppressive potency of each mouse strain MSC (B) and DF (D) were set up as described in Figure 3. CPM data were 
used to compute the SI, which is a ratio of 3H-thymidine uptake between the one-way or two-way MLR and co-cultures of the one-
way or two-way MLR + MSC or DF. The red line at SI = 3 denotes statistical biological positive whereby SI > 3 indicates significant 
stimulation of responder MNC.
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